Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 6/20 | 0.53 |
| ▸ | EGLN1 | Q9GZT9 | 9/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | FTO | Q9C0B1 | 3/20 | 0.39 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.39 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.39 |
| ▸ | FLT1 | P17948 | 2/20 | 0.39 |
| ▸ | VEGFA | P15692 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 2/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.38 |
| ▸ | KMO | O15229 | 1/20 | 0.38 |
| ▸ | TOP1 | P11387 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3758527 | 0.88 | EGLN3 (0.54) | EGLN3EGLN1MAPK1FTOKDM5B | |
| SCHEMBL3516680 | 0.87 | EGLN3 (0.55) | EGLN3EGLN1FTOKDM5BKDM2A | |
| SCHEMBL3518191 | 0.87 | EGLN3 (0.61) | EGLN3EGLN1FTOKDM5BKDM2A | |
| SCHEMBL3761711 | 0.86 | EGLN3 (0.56) | EGLN3EGLN1MAPK1FTOKDM5B | |
| SCHEMBL3519260 | 0.86 | EGLN3 (0.53) | EGLN3EGLN1FTOFLT1VEGFA | |
| SCHEMBL3519887 | 0.85 | EGLN3 (0.66) | EGLN3EGLN1FTOKDM5BKDM2A | |
| SCHEMBL3518435 | 0.84 | EGLN3 (0.60) | EGLN3EGLN1MAPK1FTOKDM5B | |
| SCHEMBL3518354 | 0.83 | EGLN3 (0.51) | EGLN3EGLN1FTOKDM5BKDM2A | |
| SCHEMBL3520878 | 0.83 | EGLN3 (0.51) | EGLN3EGLN1MAPK1 | |
| SCHEMBL3761490 | 0.83 | EGLN3 (0.55) | EGLN3EGLN1FTOKDM5BKDM2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305133-A1 | Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-12-02 | — | — | US | claimed |
| EP-2227770-A2 | PROLYL HYDROXYLASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-09-15 | — | — | EP | claimed |
| WO-2009073497-A2 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-11 | — | — | WO | claimed |
| US-20100305133-A1 | Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-12-02 | — | — | US | disclosed |
| US-20100305133-A1 | Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-12-02 | — | — | US | disclosed |
| US-20100305133-A1 | Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-12-02 | — | — | US | disclosed |
| WO-2009073497-A2 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305133-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | EGLN3 2/4885EGLN1 6/4885MAPK1 2734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.